ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
What Is Neoadjuvant Chemotherapy?
If you or a loved one has been diagnosed with cancer, your care team may recommend chemotherapy, one of the most common types of cancer treatment available. Chemotherapy involves the use of medications that Read More
What Can We Learn From A Highly Diverse Observational Study Of 17,000+ Breast Cancer Patients?
A conversation with Agendia CMO William Audeh, MD More than 17,000 patients have enrolled in Agendiaโs FLEX trial studying full genome profiling and complete clinical data for those diagnosed with stages I, II, or Read More
How Agendia is personalizing breast cancer treatment
By Abbey Bowling | October 29, 2024 October is Breast Cancer Awareness Month, andย Agendia, one of the leading providers in the field of precision oncology is working to make a significant impact in Read More
How a Pregnant Woman Diagnosed With Breast Cancer Was Helped by MammaPrint
Aleseia Saunders was 32 when she felt a lump in her right breast. Being so young with no family history of breast cancer, she shrugged it off as being a cyst and went on Read More
News
Media Releases
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, confirms results from NSABP B-42 demonstrating MammaPrint is predictive of extended endocrine therapy benefit IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 2, 2024 โ Read More
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ expanding clinical utility to optimize treatment selection. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ November 25, 2024 โ Agendiaยฎ, Inc., announced today that new data on its Read More
Agendia Co-Founder Prof. Dr. Laura vanโt Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 - Prof. Dr. Laura van 't Veer, co-founder of Agendia, pioneer in personalized cancer care and co-developer of the MammaPrintยฎ genomic breast cancer recurrence test, Read More
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX and its many sub-studies highlighting the ethnic and racial nuances that may influence treatment pathways. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ September 12, 2024 Read More